About: Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://www.biomed.cas.cz/physiolres/pdf/63/63_S327.pdf
Description	Statin-associated myopathy (SAM) represents a broad spectrum of disorders from insignificant myalgia to fatal rhabdomyolysis. Its frequency ranges from 1-5 % in clinical trials to 15-20 % in everyday clinical practice. To a large extent, these variations can be explained by the definition used. Thus, we propose a scoring system to classify statin-induced myopathy according to clinical and biochemical criteria as 1) possible, 2) probable or 3) definite. The etiology of this disorder remains poorly understood. Most probably, an underlying genetic cause is necessary for overt SAM to develop. Variants in a few gene groups that encode proteins involved in: i) statin metabolism and distribution (e.g. membrane transporters and enzymes; OATP1B1, ABCA1, MRP, CYP3A4), ii) coenzyme Q10 production (e.g. COQ10A and B), iii) energy metabolism of muscle tissue (e.g. PYGM, GAA, CPT2) and several others have been proposed as candidates which can predispose to SAM. Pharmacological properties of individual statin molecules (e.g. lipophilicity, excretion pathways) and patients' characteristics influence the likelihood of SAM development. This review summarizes current data as well as our own results. Statin-associated myopathy (SAM) represents a broad spectrum of disorders from insignificant myalgia to fatal rhabdomyolysis. Its frequency ranges from 1-5 % in clinical trials to 15-20 % in everyday clinical practice. To a large extent, these variations can be explained by the definition used. Thus, we propose a scoring system to classify statin-induced myopathy according to clinical and biochemical criteria as 1) possible, 2) probable or 3) definite. The etiology of this disorder remains poorly understood. Most probably, an underlying genetic cause is necessary for overt SAM to develop. Variants in a few gene groups that encode proteins involved in: i) statin metabolism and distribution (e.g. membrane transporters and enzymes; OATP1B1, ABCA1, MRP, CYP3A4), ii) coenzyme Q10 production (e.g. COQ10A and B), iii) energy metabolism of muscle tissue (e.g. PYGM, GAA, CPT2) and several others have been proposed as candidates which can predispose to SAM. Pharmacological properties of individual statin molecules (e.g. lipophilicity, excretion pathways) and patients' characteristics influence the likelihood of SAM development. This review summarizes current data as well as our own results. (en)
Title	Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management (en)
skos:prefLabel	Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management (en)
skos:notation	RIV/00216208:11110/14:10285465!RIV15-MSM-11110___
http://linked.open...avai/riv/aktivita	V
http://linked.open...avai/riv/aktivity	V
http://linked.open...iv/cisloPeriodika	Suppl. 3
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Schwarzová, Lucie Vrablík, Michal Zlatohlávek, Lukáš Češka, Richard Prusíková, Martina Štulc, Tomáš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 1. lékařská fakulta
http://linked.open...dnocenehoVysledku	47308
http://linked.open...ai/riv/idVysledku	RIV/00216208:11110/14:10285465
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Genetics; Risk score; Definition; Statin associated myopathy; Statins (en)
http://linked.open.../riv/klicoveSlovo	Genetics Risk score Statin associated myopathy Statins Definition
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[25480401BC2A]
http://linked.open...i/riv/nazevZdroje	Physiological Research
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	63
http://linked.open...iv/tvurceVysledku	Vrablík, Michal Zlatohlávek, Lukáš Češka, Richard Prusíková, Martina Štulc, Tomáš Hubáček, J. A Schwarzová, Lucie Adamková, V.
http://linked.open...ain/vavai/riv/wos	000345591100002
issn	0862-8408
number of pages	8 (xsd:int)
http://localhost/t...ganizacniJednotka	11110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software